Terminated PHASE3 INTERVENTIONAL NCT00175305

Prader-Willi Syndrome and Appetite

Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With Prader-Willi Syndrome

Sponsor: University of British Columbia

Conditions Hyperphagia Prader-Willi Syndrome

Interventions Sandostatin LAR

Updated 5 times since 2017 Last updated: Oct 29, 2007 Started: Aug 31, 2004 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from University of British Columbia

See all terminations from University of British Columbia

Other Hyperphagia trials with similar outcome

NCT03790865 · Phase PHASE2/PHASE3 · May 2020

Browse all Hyperphagia trials

This PHASE3 trial investigates Hyperphagia and Prader-Willi Syndrome and is currently terminated or withdrawn. University of British Columbia leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of British Columbia

Data source: University of British Columbia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada